Coukos and colleagues conduct a phase 1 study to evaluate the benefit of adoptive transfer of ex vivo-expanded, vaccine-primed T cells in patients with ovarian cancer—a cancer type that often does not respond to immune checkpoint blockade.
- Sara Bobisse
- Valentina Bianchi
- George Coukos